Background In phase 2 studies, baricitinib, an oral Janus kinase 1 and 2 inhibitor, reduced
disease activity in patients with rheumatoid arthritis who had not previously received …

Baricitinib is an oral Janus kinase (JAK) 1/JAK 2 inhibitor approved for the treatment of
rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) …

Objectives To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral
inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA) despite …

Numerous cytokines have been implicated in the pathogenesis of inflammatory diseases,
and their dysregulation is a main feature of rheumatoid arthritis (RA). Cytokines stimulate …

Objectives Lipid profiles are altered by active disease in patients with rheumatoid arthritis
(RA) and may be further modified by treatment with Janus kinase inhibitors and other …

Objectives To assess baricitinib on patient-reported outcomes (PROs) in patients with
moderately to severely active rheumatoid arthritis, who had insufficient response or …

Objective. To assess the safety and efficacy of baricitinib in patients with rheumatoid arthritis
(RA) up to 128 weeks in a phase IIb study (NCT01185353). Methods. After a 24-week …

The purpose of the study was to assess the proportion of patients who achieve pain relief
thresholds, the time needed to reach the thresholds, and the relationship between pain and …

Objective RA patients who have failed biologic DMARDs (bDMARDs) represent an unmet
medical need. We evaluated the effects of baseline characteristics, including prior bDMARD …

Objective To assess the effects of baricitinib on lipid profiles in patients with moderate‐to‐
severe rheumatoid arthritis. Methods Treatment with once‐daily doses of baricitinib (1, 2, 4 …